Sign In
Buy REGN
$618.95
+16.03 (+2.66%)
At Close: Jun 03, 2026
Baird Chautauqua International Growth Fund: Q4 2025 Winners, Laggards, Buys & Sells
05:45am, Friday, 13'th Feb 2026
Baird Chautauqua International Growth Fund underperformed its benchmark as stock selection in health care and consumer discretionary detracted most from relative returns. Fanuc reported September quar
Will Eylea Sales Decline Weigh on REGN's Top Line in 2026?
10:31am, Thursday, 12'th Feb 2026
Regeneron foresees further Eylea decline in 2026 as biosimilars loom, but Eylea HD, Dupixent and Libtayo aim to steady revenues.
Regeneron Announces Investor Conference Presentations
04:05pm, Wednesday, 11'th Feb 2026
TARRYTOWN, N.Y., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:
Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy
07:00am, Tuesday, 10'th Feb 2026
36 abstracts to be presented across Regeneron-invented therapies, including first-time Phase 3 presentations for two distinct investigational allergen-blocking antibodies for cat and birch allergies
Thrivent Financial for Lutherans Sells 1,978 Shares of Regeneron Pharmaceuticals, Inc. $REGN
04:18am, Sunday, 08'th Feb 2026
Thrivent Financial for Lutherans reduced its position in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 20.8% in the undefined quarter, according to its most recent filing with the SEC. The firm ow
Optimize Financial Inc Purchases New Position in Regeneron Pharmaceuticals, Inc. $REGN
04:24am, Thursday, 05'th Feb 2026
Optimize Financial Inc bought a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) during the undefined quarter, according to its most recent filing with the SEC. The institution
Mediolanum International Funds Ltd Trims Stock Position in Regeneron Pharmaceuticals, Inc. $REGN
05:02am, Wednesday, 04'th Feb 2026
Mediolanum International Funds Ltd reduced its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 65.1% during the undefined quarter, according to its most recent filing with the Securities an
Machina Capital S.A.S. Invests $2.60 Million in Regeneron Pharmaceuticals, Inc. $REGN
05:02am, Wednesday, 04'th Feb 2026
Machina Capital S.A.S. purchased a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) during the third quarter, according to its most recent disclosure with the Securities and Excha
Principal Financial Group Inc. Decreases Stake in Regeneron Pharmaceuticals, Inc. $REGN
05:02am, Wednesday, 04'th Feb 2026
Principal Financial Group Inc. lowered its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 3.9% during the undefined quarter, according to the company in its most recent filing
These Analysts Revise Their Forecasts On Regeneron Pharmaceuticals After Q4 Results
12:13pm, Monday, 02'nd Feb 2026
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) on Friday reported upbeat fourth-quarter earnings.
New presentations include final 64-week results from the Phase 3 QUASAR trial in patients with retinal vein occlusion, as well as full primary results from the Phase 3b ELARA trial in patients treated
Great Lakes Advisors LLC Makes New Investment in Regeneron Pharmaceuticals, Inc. $REGN
04:21am, Monday, 02'nd Feb 2026
Great Lakes Advisors LLC acquired a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) during the undefined quarter, according to the company in its most recent 13F filing with t
Regeneron: Expect Double-Digit Growth In 2026
08:33am, Saturday, 31'st Jan 2026
Regeneron is poised for double-digit revenue and EPS growth in 2026, driven by Dupixent and reduced Eylea headwinds. Dupixent's robust expansion and pipeline successors support Regeneron's long-term g
Regeneron Pharmaceuticals Inc (REGN) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Advancements
04:02pm, Friday, 30'th Jan 2026
Total Revenue: $3.9 billion in Q4 2025, up 3% year-over-year.Dupixent Global Net Sales: $4.9 billion in Q4 2025, $17.8 billion for the full year 2025.Libtayo G
Regeneron Pharmaceuticals, Inc. (REGN) Q4 2025 Earnings Call Transcript
03:10pm, Friday, 30'th Jan 2026
Regeneron Pharmaceuticals, Inc. (REGN) Q4 2025 Earnings Call Transcript
